Eyenovia, Inc. Secures $1.9 Million in Direct Stock Offering
Eyenovia, Inc. (NASDAQ: EYEN) has announced an important step towards advancing ophthalmic treatment technologies. This dynamic company, known for its innovative Optejet platform, revealed a newly established securities purchase agreement with a healthcare-focused institutional investor. This agreement entails the purchase and sale of over 20 million shares of common stock and accompanying warrants, culminating in a total offering priced at approximately $1.9 million.
Details of the Offering
The registered direct offering involves not only the sale of 20,085,025 shares but also warrants that allow for the purchase of up to 40,170,050 additional shares. The offering price set at $0.0969 per share reflects Eyenovia's commitment to improving access for its investors and supporters. The exercise price of the warrants will also mirror this price, and they will be exercisable six months from their issuance, with a lifespan of five years once they become active.
Strategic Allocation of Proceeds
The funds generated from this offering are expected to bolster Eyenovia's operational capabilities, focusing particularly on working capital necessities and overall corporate objectives. The net proceeds may facilitate a range of initiatives including the repayment of existing loans, the advancement of the next generation of the Optejet device, and commercial activities related to their products like Mydcombi and clobetasol propionate.
Support from Industry Experts
To ensure this offering reaches its full potential, Eyenovia has enlisted Chardan to act as the sole placement agent, providing their expertise to navigate the complexities of securities offerings. Chardan's involvement is set to enhance the overall efficiency and effectiveness of the offering process.
Registration and Compliance
This offering is being conducted under the provisions of Eyenovia's previously filed shelf registration statement on Form S-3 with the Securities and Exchange Commission (SEC), which means that detailed information regarding the offering will be accessible to interested parties. This transparency is essential for maintaining trust with investors and stakeholders.
About Eyenovia, Inc.
Eyenovia, Inc. is at the forefront of innovation in ophthalmic technology, focusing on developing products that leverage its unique Optejet platform. This cutting-edge system is particularly advantageous for treating chronic front-of-the-eye conditions due to its user-friendly design and potential for enhanced patient compliance when compared to traditional eye drop solutions.
Current Product Lineup
The company’s existing products include clobetasol propionate ophthalmic suspension, used primarily for managing post-surgical pain and inflammation, and Mydcombi, which aids in the dilation of pupils for medical examinations. These advancements not only improve treatment options but also strive to elevate patient care standards.
Future Vision
Eyenovia envisions continuing to explore strategic partnerships and alternatives that amplify shareholder value. The company's commitment to innovation and enhancing the patient experience positions it well for future success in the ophthalmic industry.
Frequently Asked Questions
What is the total amount raised in Eyenovia's latest offering?
The recent offering raised approximately $1.9 million.
Who is the placement agent for this offering?
Chardan is acting as the sole placement agent for the offering.
What innovations does Eyenovia focus on?
Eyenovia specializes in ophthalmic technologies, particularly through its proprietary Optejet platform.
How will the proceeds from the offering be allocated?
The proceeds will support working capital, repayment of loans, and advancement of product commercialization efforts.
What are the benefits of the Optejet technology?
The Optejet technology enhances medication delivery with improved safety, usability, and patient compliance compared to standard eye drops.
